A Randomised, Placebo-Controlled, Double-Dummy, Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GSK561679 and Lorazepam (Comparator) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Lorazepam; Verucerfont
- Indications Depressive disorders; Social phobia
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 12 Aug 2009 Actual patient number (22) added as reported by ClinicalTrials.gov.
- 12 Aug 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 12 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.